NasdaqGS:NVAXBiotechs
Will Novavax’s New R&D Chief Reframe Its Partnership-Led Strategy and Long-Term Story (NVAX)?
Novavax recently appointed Dr. Robert Walker as Executive Vice President and Head of Research & Development, succeeding Dr. Ruxandra Draghia-Akli and placing him in charge of all preclinical and clinical R&D activities.
With more than three decades in drug and vaccine development and prior leadership as Novavax’s Chief Medical Officer, Dr. Walker’s expanded role could meaningfully shape how the company prioritizes and executes its vaccine and adjuvant pipeline.
Next, we’ll assess how...